二甲双胍联合EGFR-TKI治疗EGFR突变肺腺癌的2期随机试验
这项在墨西哥开展的开放标签2期随机试验纳入139例晚期EGFR突变肺腺癌患者,比较EGFR-TKI联合二甲双胍与单用EGFR-TKI的疗效。
要点
- 二甲双胍联合EGFR-TKI较单用TKI显著改善PFS(HR 0.60)。
- 联合组中位OS亦显著延长(31.7 vs 17.5个月)。
- 结果支持开展3期安慰剂对照研究。
核心结论
- 在晚期EGFR突变肺腺癌患者中,二甲双胍联合标准EGFR-TKI治疗较单用EGFR-TKI显著改善无进展生存期。
研究设计与样本
- 开放标签、随机、2期试验,在墨西哥城Instituto Nacional de Cancerología开展。
- 纳入139例18岁以上、组织学确诊IIIB-IV期伴激活EGFR突变的肺腺癌患者,随机分入EGFR-TKI组(n=70)或EGFR-TKI联合二甲双胍组(n=69)。
关键数值与推荐
- 二甲双胍用法为500 mg每日两次,与标准剂量厄洛替尼、阿法替尼或吉非替尼联用。
- 治疗持续至出现不可耐受毒性或撤回知情同意。
临床怎么用
- 对于晚期EGFR突变肺腺癌患者,在标准EGFR-TKI治疗基础上加用二甲双胍可能改善PFS和OS。
- 该结果尚需3期安慰剂对照试验验证后方可改变临床实践。
局限性
- 为开放标签2期试验,样本量有限(共139例),非安慰剂对照。
- 研究仅在墨西哥单中心开展,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metformin hydrochloride is emerging as a repurposed anticancer drug. Preclinical and retrospective studies have shown that it improves outcomes across a wide variety of neoplasms, including lung cancer. Particularly, evidence is accumulating regarding the synergistic association between metformin and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). OBJECTIVE: To assess the progression-free survival (PFS) in patients with advanced lung adenocarcinoma who received treatment with EGFR-TKIs plus metformin compared with those who received EGFR-TKIs alone. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized, phase 2 trial conducted at the Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. Eligible patients were 18 years or older, had histologically confirmed stage IIIB-IV lung adenocarcinoma with an activating EGFR mutation. INTERVENTIONS: Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice a day) or EGFR-TKIs alone. Treatment was continued until occurrence of intolerable toxic effects or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary outcome was PFS in the intent-to-treat population. Secondary outcomes included objective response rate, disease control rate, overall survival (OS), and safety. RESULTS: Between March 31, 2016, and December 31, 2017, a total of 139 patients (mean [SD] age, 59.4 [12.0] years; 65.5% female) were randomly assigned to receive EGFR-TKIs (n = 70) or EGFR-TKIs plus metformin (n = 69). The median PFS was significantly longer in the EGFR-TKIs plus metformin group (13.1; 95% CI, 9.8-16.3 months) compared with the EGFR-TKIs group (9.9; 95% CI, 7.5-12.2 months) (hazard ratio, 0.60; 95% CI, 0.40-0.94; P = .03). The median OS was also significantly longer for patients receiving the combination therapy (31.7; 95% CI, 20.5-42.8 vs 17.5; 95% CI, 11.4-23.7 months; P = .02). CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first study to prospectively show that the addition of metformin to standard EGFR-TKIs therapy in patients with advanced lung adenocarcinoma significantly improves PFS. These results justify the design of a phase 3, placebo-controlled study. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03071705.
引用
- Arrieta O, Barrón F, Padilla MS, et al. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31486833. doi:10.1001/jamaoncol.2019.2553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。